By data cutoff ( Dec 2 , 2009 ) , 113 ( 78 % ) patients had progressed ( 52 [ 72 % ] patients in the vandetanib group and 61 [ 84 % ] in the placebo group ) and 40 ( 28 % ) had died ( 19 [ 26 % ] patients in the vandetanib group and 21 [ 29 % ] in the placebo group ) .
